<DOC>
	<DOCNO>NCT00036413</DOCNO>
	<brief_summary>This study first perform Amyotrophic Lateral Sclerosis ( ALS ) patient novel compound TCH346 . Its purpose evaluate safety clinical effect 3 dose level TCH 346 compare placebo patient clinical diagnosis laboratory-supported probable , probable definite ALS . The study require patient visit study center total least 7 time course 14 week . The study consist 2 phase : A screening phase ( 2 week ) patient evaluate eligibility participate study , double-blind treatment phase ( 12 week ) patient receive daily dos either TCH346 placebo evaluate clinical effect . In addition , patient eligible participate study require 3 magnetic resonance spectroscopic ( MRS ) scan . The MRS non-invasive , painless , `` brain scan '' . The MRS require travel designate center Montreal , Canada , experience perform MRS scan ALS patient .</brief_summary>
	<brief_title>A 12-week , Multicenter , Safety Dose-ranging Study 3 Oral Doses TCH346 Patients With Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>clinical diagnosis laboratorysupported probable , probable , definite ALS ; sporadic familial ALS ; show ALS symptom onset 3 yrs. , inclusive , prior randomization ; FVC &gt; 60 % ; ability tolerate MRS evaluation</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>( ALS )</keyword>
</DOC>